PMID: 8581379Oct 1, 1995Paper

Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions

Journal of Hematotherapy
S CanevariG Bolis

Abstract

The high frequency of relapse after induction chemotherapy in advanced ovarian carcinoma patients calls for new therapeutic modalities. Retargeted T cell-mediated lysis can be achieved using the bispecific antibody (BsmAb) OCTR, directed to CD3 on T cells and to the folate receptor on ovarian carcinoma cells. Twenty-eight patients with limited intraperitoneal disease after first-line therapy entered a phase II study. They received two i.p. 5 day cycles of activated PBMC retargeted with OCTR. Despite unfavorable tumor characteristics, 7 of 26 patients (27%) showed complete or partial intraperitoneal responses with strict surgicopathologic evaluation. In most cases, the disease relapsed outside the peritoneal cavity, and in 1 case complete intraperitoneal response was accompanied by progression in retroperitoneal lymph nodes. The morbidity was mild to moderate and transient. Combination of i.v. and i.p. administration of OCTR-retargeted lymphocytes will possibly lead to extraperitoneal cure. Ongoing clinical studies indicate that the i.v. infusion of up to 8 x 10(8) OCTR-retargeted T lymphocytes does not induce a higher toxicity than the i.p. treatment. To avoid PBMC preactivation, new approaches for delivering accessory signals ...Continue Reading

References

Oct 1, 1991·European Journal of Immunology·G JungW Wilmanns
Mar 15, 1987·International Journal of Cancer. Journal International Du Cancer·S MiottiM I Colnaghi
Sep 15, 1988·International Journal of Cancer. Journal International Du Cancer·S M PupaM I Colnaghi
Jan 1, 1987·European Journal of Immunology·A Lanzavecchia, D Scheidegger
Apr 15, 1988·International Journal of Cancer. Journal International Du Cancer·D MezzanzanicaM I Colnaghi
Jun 1, 1973·American Journal of Obstetrics and Gynecology·C M BagleyV T DeVita
Jan 5, 1994·Journal of the National Cancer Institute·E C KohnF P Ognibene
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F CrippaE Bombardieri
Oct 1, 1994·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·R S FreedmanS Templin
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E L TrimbleR Hayn
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A E TaylorC Fisher
Sep 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C DittrichP Sevelda

❮ Previous
Next ❯

Citations

Apr 20, 2004·Advanced Drug Delivery Reviews·Hala Elnakat, Manohar Ratnam
Aug 23, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yingjuan Lu, Philip S Low
Jun 6, 2000·Advanced Drug Delivery Reviews· de Leij LB J Kroesen
Mar 4, 2000·Advanced Drug Delivery Reviews·J Sudimack, R J Lee
Apr 1, 2008·Expert Opinion on Drug Discovery·Constantin N Baxevanis
Jan 23, 2010·Expert Opinion on Biological Therapy·Whitney A SpannuthRobert L Coleman
Jul 2, 2003·Expert Opinion on Biological Therapy·Manohar RatnamXing Pan
Feb 11, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Priyanka BhattRajashree Mashru
May 9, 2012·Drug Discovery Today·Janice M Reichert, Eugen Dhimolea
Oct 24, 2007·Cancer Letters·Markus Jensen, Frank Berthold
Jan 18, 2006·Experimental Hematology·Lawrence G LumRandall J Lee
Mar 17, 1999·Journal of Chemotherapy·T M Trippett, J R Bertino
Sep 24, 2016·American Journal of Surgery·Masha ZeltsmanPrasad S Adusumilli
May 18, 2018·Immunology·Muzamil Y WantKunle Odunsi
Mar 20, 1998·International Journal of Cancer. Journal International Du Cancer·S RiedleM Zöller
Oct 1, 1996·Journal of Hematotherapy·A DwengerR Mertelsmann
Sep 2, 1999·International Journal of Cancer. Journal International Du Cancer·K A SmansJ L Millán
Nov 10, 2011·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Alberto ZacchettiSilvana Canevari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.